Literature DB >> 11722595

Increased cell surface expression of C-terminal truncated erythropoietin receptors in polycythemia.

T Motohashi1, Y Nakamura, M Osawa, T Hiroyama, A Iwama, A Shibuya, H Nakauchi.   

Abstract

Primary familial and congenital polycythemia (PFCP) is a disorder characterized by an increased number of erythrocytes despite normal blood oxygen pressure and a normal serum erythropoietin (EPO) level. Recent studies revealed that erythroid progenitor cells from certain individuals with PFCP express various forms of EPO receptor (EPOR) truncated at the terminal carboxyl site (EPOR-TTC(PFCP)). EPOR-TTC(PFCP) can transmit EPO-mediated proliferative signals more efficiently than can full-length EPOR (EPOR-F), at least partly because of defective recruitment of SHP-1 phosphatase to these receptors. In agreement with previous studies, Ba/F3 transfectants expressing EPOR-TTC(PFCP) showed higher proliferative responses to EPO. In those transfectants, we found that EPOR-TTC(PFCP) was expressed more abundantly on the cell surface than was EPOR-F. This tendency was confirmed by a transient-expression experiment using COS7 cells. Since expression levels of EPOR protein were not significantly different among these transfectants, differences in cell surface expression were likely dependent on post-translational mechanism(s). In addition to defective recruitment of SHP-1 to EPOR-TTC(PFCP), more efficient transport and expression on the cell surface appear to serve as mechanisms responsible for increased EPO-responsiveness of erythroid progenitor cells in PFCP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11722595     DOI: 10.1034/j.1600-0609.2001.t01-1-00446.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.

Authors:  Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2007-11       Impact factor: 2.303

Review 3.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

4.  Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion.

Authors:  Olivier Negre; Floriane Fusil; Charlotte Colomb; Shoshannah Roth; Beatrix Gillet-Legrand; Annie Henri; Yves Beuzard; Frederic Bushman; Philippe Leboulch; Emmanuel Payen
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

5.  An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation.

Authors:  Orly Ravid; Imad Shams; Nathalie Ben Califa; Eviatar Nevo; Aaron Avivi; Drorit Neumann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-27       Impact factor: 11.205

6.  Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.

Authors:  Rita Sulahian; Ondine Cleaver; Lily Jun-shen Huang
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113

7.  Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.

Authors:  Pardeep Heir; Tharan Srikumar; George Bikopoulos; Severa Bunda; Betty P Poon; Jeffrey E Lee; Brian Raught; Michael Ohh
Journal:  J Biol Chem       Date:  2016-02-04       Impact factor: 5.157

8.  Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles.

Authors:  Seema Singh; Rakesh Verma; Anamika Pradeep; Karen Leu; R Bruce Mortensen; Peter R Young; Miho Oyasu; Peter J Schatz; Jennifer M Green; Don M Wojchowski
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.